Milan, Italy – Sibylla Biotech has strengthened its leadership team with the appointments of Stefan Ries, PhD, as Chief Scientific Officer (CSO), and Elena Ardini, MSc, as Vice President of Research and Development (R&D). The company believes these additions will accelerate its preclinical and clinical development programs.
Ries brings over two decades of experience in drug discovery and development, with a focus on oncology. His background includes leadership roles at DISCO Pharmaceuticals and Versant Ventures, as well as a significant tenure at Hoffmann-La Roche. He holds a PhD in Biochemistry from the University of Regensburg and completed postdoctoral work at the University of California, San Francisco.
Ardini is a seasoned oncology expert with more than 20 years in drug discovery. She previously held various leadership positions at Nerviano Medical Sciences, where she played a key role in the development of entrectinib/Rozlytrek®. She earned a master’s degree in Biological Sciences from the University of Milan.
Sibylla Biotech’s Co-Founder and CEO, Lidia Pieri, PhD, MBA, highlighted the importance of these appointments. She emphasized that Ries and Ardini’s expertise and commitment to innovative therapeutics will be crucial as the company advances its pipeline of small molecule drug candidates. She noted that their experience aligns well with Sibylla’s corporate culture.
Ries expressed his enthusiasm for joining Sibylla Biotech at this pivotal moment, stating the company’s novel approach to targeted protein degradation holds significant potential. He looks forward to contributing to the company’s growth and strategic direction.
Ardini also shared her excitement, emphasizing the opportunity to work with a dedicated team on a technology with the potential to address unmet medical needs. She is eager to apply the PPI-FIT technology to advance promising drug candidates.
Sibylla Biotech is developing a novel approach to drug discovery focused on targeting protein folding intermediates. This unique strategy aims to address previously “undruggable” targets. The company’s proprietary PPI-FIT technology platform allows it to predict and target intermediate steps in the protein folding process, leading to targeted protein degradation. Sibylla Biotech is actively pursuing treatments for various diseases with significant unmet medical needs.
Related
